文献速递泌尿生殖与妇科肿瘤放疗

3D打印近距离放疗用于宫颈癌患者:改善疗效与安全性结局

3D-printed brachytherapy in patients with cervical cancer: improving efficacy and safety outcomes.
PubMed 文献 · Radiat Oncol · 2024-11-02

本研究纳入2019年1月至2023年7月赣南医学院第一附属医院治疗的50例宫颈癌患者,比较调强放疗联合3D打印近距离放疗(25例)与调强放疗联合徒手植入近距离放疗(25例)的疗效与安全性。3D打印组放射性肠炎发生率显著低于徒手植入组(29.2% vs 88%,p<0.001),两组短期疗效与总生存无显著差异。

要点

  • 3D打印近距离放疗组放射性肠炎发生率为29.2%,徒手植入组为88%,差异有统计学意义(p<0.001)。
  • 两组放射性膀胱炎发生率分别为79.2%与64%,差异无统计学意义(p=0.240)。
  • 两组短期疗效反应率可比,总生存无显著差异。

核心结论

  • 3D打印近距离放疗为宫颈癌患者提供了更有效且更安全的治疗选择,尤其适用于大肿瘤或复杂解剖结构的患者。

研究设计与样本

  • 本研究纳入2019年1月至2023年7月赣南医学院第一附属医院治疗的50例宫颈癌患者,分为3D打印近距离放疗组(25例,调强放疗联合3D打印近距离放疗)与徒手植入组(25例,调强放疗联合徒手植入近距离放疗)。

主要发现

  • 3D打印近距离放疗组放射性肠炎发生率为29.2%,徒手植入组为88%,3D打印组显著低于徒手植入组(p<0.001)。
  • 3D打印近距离放疗组放射性膀胱炎发生率为79.2%,徒手植入组为64%,两组差异无统计学意义(p=0.240)。
  • 两组短期疗效反应率可比,总生存无显著差异。
  • 3D打印近距离放疗通过提供更精确的剂量分布,降低膀胱和直肠等危及器官所受的辐射剂量,从而改善了大肿瘤(≥30 mm)放疗操作的安全性。
  • 本研究的中位随访时间为22.5个月(四分位距18-29)。

关键数值与推荐

  • 3D打印近距离放疗组放射性肠炎发生率为29.2%,徒手植入组为88%(p<0.001)。
  • 3D打印近距离放疗组放射性膀胱炎发生率为79.2%,徒手植入组为64%(p=0.240)。
  • 49例患者中43例为宫颈鳞癌,6例为宫颈腺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to evaluate the efficacy and safety of 3D printing technology in brachytherapy for cervical cancer, comparing its outcomes with conventional free hand implantation brachytherapy. METHODS: A total of 50 cervical cancer patients treated at the First Affiliated Hospital of Gannan Medical College from January 2019 to July 2023 were included in this study. Patients were divided into two groups: 25 patients received intensity-modulated radiotherapy (IMRT) combined with 3D-printed brachytherapy, and 25 patients underwent IMRT combined with free hand brachytherapy implantation. Key indicators analyzed included short-term therapeutic effects, survival outcomes, operation times, the number of CT scans, the number of needles inserted, dosimetric parameters, and complications. RESULTS: The use of 3D-printed brachytherapy significantly improved the safety of radiation therapy operations, especially for large tumors (≥ 30 mm), by providing more precise dose distribution and reducing the radiation doses received by critical organs such as the bladder and rectum. Compared to the artificial implant group (88% prevalence), the 3D-printed brachytherapy group showed a significantly lower incidence of radiation enteritis (29.2% prevalence, p < 0.001). There were no significant differences in other complications between the two groups. For instance, the incidence of radiation cystitis was relatively high in the 3D-printed brachytherapy group (79.2% prevalence) compared to the artificial implant group (64% prevalence, p = 0.240). The median follow-up period in this study was 22.5 months [IQR 18-29]. Among the 49 patients included, 43 had cervical squamous carcinoma and 6 had cervical adenocarcinoma. Short-term therapeutic response rates were comparable, with no significant difference in overall survival observed between the two groups. CONCLUSION: 3D-printed brachytherapy offers a more effective and safer therapeutic option for patients with cervical cancer, particularly for those with large tumors or complex anatomical structures.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lu Z, Zhu G, Qiu Z, et al. 3D-printed brachytherapy in patients with cervical cancer: improving efficacy and safety outcomes. Radiat Oncol. 2024. PMID: 39488692. doi:10.1186/s13014-024-02536-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。